Kaléo has been selected by the U.S. Department of Defense to develop the Reconstitution Auto-Injector Device – Atropine (RAD-A), the next generation nerve agent countermeasure. bit.ly/KaleoMCM #Defense #Medicalcountermeasure #MCM

Kaléo welcomes George Parise as CFO and congratulates Steve Gaeth on his new role as VP & Controller. Read more: bit.ly/4322X6A

Kaléo welcomes Christine Waite as Vice President, Marketing & Analytics. Read more: bit.ly/3m4w4Xx

Mark Herzog of our Government Sector business unit was in London this week representing Kaléo at the Deployed Medical & Healthcare Delivery Conference. Visitors learned about our #medicalcountermeasures designed to keep troops on-mission. #DMHD2023 #CBRN #Defense

We are at #NAPNAPconf this week in Orlando, Florida. Visit us at Booth #220 and learn more about how to recognize the signs and symptoms of anaphylaxis. #medicalscience #continuedlearning

Pleased to share that @Kaleo and Parexel won a Quality Award from the Abstract Committee of the American Conference on Pharmacometrics. The research focuses on Naloxone Auto-Injector (NAI) 10 mg and its reversal effects of different opioids. bit.ly/3uK2dEw.

Kaléo announces the appointment of Major General Elder Granger, M.D., U.S. Army, (Ret) to its Board. Read more: bit.ly/3gt2ckr

Mark Herzog and Gary Riddle of our Government Sector business unit are exhibiting at the FUTURE FORCES FORUM this week in Prague. Visit our booth to learn more about our Rapid Opioid Countermeasure System (ROCS). #military #defense

Raise awareness of food allergy bullying during #BullyingPreventionMonth . Show others that you have #NoAppetiteforBullying . Learn more: bit.ly/3CrQ8Yc

We are at #AAP2022 this week in Anaheim, California. Visit us at Booth #2605 and learn more about how to recognize the signs and symptoms of anaphylaxis.

#medicalscience #continuedlearning

The Kaléo team takes pride in our state-of-the-art manufacturing systems and real-time commitment to improvement, always working with a quality first mind-set.

Kaléo welcomes Ted A. Marcuccio as Chief Business Officer. Read more: bit.ly/3dLS9Gh

Kaléo announces its first contract with the U.S. Department of Defense for the procurement of the Rapid Opioid Countermeasure System, a 10 Naloxone Auto-injector (naloxone hydrochloride injection) antidote for ultra-potent weaponized opioids. Read more: bit.ly/3Sem5JW

Congratulations to the JPEO-CBRND Rapid Opioid Countermeasure System (ROCS) product team on their Award for Outstanding Product Management at the 2022 #MHSRS bit.ly/ROCS-Award
#MHSRS #military #research

The Kaléo team is excited to be attending the #2022MHSRS Conference in Florida this week. @usamrdc #cbrn JPEO-CBRND

Kaléo welcomes Alfred Tenuto as Chief Commercial Officer, and announces a new Government Sector business unit, led by Mark Herzog, VP, Global Corporate Affairs, Defense & Homeland Security. Read more: bit.ly/3QBD08h

Today we announced an exciting partnership for patients & families across Canada with serious allergic reactions. Kaléo has entered into a license agreement with Valeo Pharma to promote & market ALLERJECT® (epinephrine injection, USP) in Canada. bit.ly/ALLERJECT_vp

We are at #aanp22 this week in Orlando, Florida. Visit us at Booth #1306 and learn more about how to recognize the signs and symptoms of pediatric anaphylaxis. #medicalscience #continuedlearning

The Kaléo team is committed to developing meaningful and innovative solutions for patients to live fuller and bolder lives.

At Kaléo, Winning Teamwork means that we are committed to help each other, listen intently, communicate openly, motivate and mentor each other.